Vemurafenib Pregnancy and Breastfeeding Warnings
Vemurafenib is also known as: Zelboraf
Vemurafenib Pregnancy Warnings
Vemurafenib has been assigned to pregnancy category D by the FDA. Animal studies have failed to reveal evidence of teratogenicity. There are no adequate and well controlled data in human pregnancy. Women of childbearing potential and men should be advised to use appropriate contraceptive measures during vemurafenib therapy and for at least 2 months after discontinuation of vemurafenib. If vemurafenib is used during pregnancy or if the patient becomes pregnant during treatment, the patient should be advised of the potential hazard to the developing fetus.
Vemurafenib Breastfeeding Warnings
There are no data on the excretion of vemurafenib in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions from vemurafenib in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
See Also...
- vemurafenib Consumer Information
- Pregnancy Support Group
- FDA Pregnancy Categories
- Medicine use during Pregnancy
- Medicine use while Breastfeeding
- Safe Medications during Breastfeeding
Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and Drugs.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This drug information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information in contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.
